Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Invest. 2011 Oct;29(8):501-10. doi: 10.3109/07357907.2011.606248. Epub 2011 Aug 15.

Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.

Author information

  • 1Division of Translational Vaccine Research, City of Hope National Medical Center, Duarte, California, USA.

Abstract

The p53 gene product is an attractive target for tumor immunotherapy. The present study aims to understand the potential of MVAp53 vaccine to induce expansion of p53-specific cytotoxic T lymphocyte ex vivo in cancer patients. The result indicated that 14 of 23 cancer patients demonstrated p53-specific IFN-γ production, degranulation, cell proliferation, and lysis of p53 overexpressed human tumor cell lines. These experiments show that MVAp53 stimulation has the potential to induce the expansion of p53-specific cytotoxic T lymphocyte from the memory T cell repertoire. The data suggest that MVAp53 vaccine is an ideal candidate for cancer immunotherapy.

PMID:
21843052
[PubMed - indexed for MEDLINE]
PMCID:
PMC3260009
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk